AdvanCell

AdvanCell has been awarded funding under the Queensland Government’s Sovereign Industry Development Fund to establish Australia’s first capability to produce Thorium 228, a critical input for next-generation cancer treatments.

The Queensland Government’s catalytic investment will strengthen Queensland’s position as a global leader in the production of targeted alpha therapies and as one of the only jurisdictions in the world producing Thorim-228 at commercial scale.

The project will establish new sovereign capabilities for Queensland and accelerate access to life-changing medical treatments.